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Abstract
The World Health Organisation recommends exclusive 
breastfeeding for the first six months of an infant’s 
life and in combination with solid food thereafter. This 
recommendation was introduced based on research 
showing numerous health benefits of breastfeeding 
for both the mother and the infant. However, there is 
always concern regarding the transfer of medications 
from mother to their breastfed baby via  milk. Pharma-
cokinetic properties of a drug are usually used to pre-
dict its transferability into breast milk. Although most 
drugs are compatible with breastfeeding, cases of toxic 
drug exposure have been reported. This is thought to 
be due to active transport mechanisms whereby efflux 
transporter proteins expressed in the epithelial cells of 
the mammary gland actively secrete drugs into milk. An 
example of such efflux transporters including the breast 
cancer resistance protein which is strongly induced dur-
ing lactation and this could result in contamination of 
milk with the substrates of this transporter which may 
place the suckling infant at risk of toxicity. Furthermore, 
there is little known about the substrate specificity of 
most efflux transporters as we have highlighted in this 
review. There also exists some degree of contradiction 
between in vivo  and in vitro  studies which makes it dif-
ficult to conclusively predict outcomes and drug-drug 
interactions. 
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Core tip: The aim of this review was to analyse the 
available literature on psychoactive drugs specifically 
selective serotonin reuptake inhibitors, antipsychotics 
and antiepileptic drugs that are commonly prescribed 
during lactation and pregnancy. This review investigat-
ed whether these drugs are substrates and/or inhibitors 
of efflux transporters especially of P-glycoprotein and 
breast cancer resistance protein and whether this has 
any effect on adverse outcomes in the breastfed infant 
of mothers who use these pharmacotherapeutic agents. 
Current evidence on acute adverse effects in breastfed 
infants due to the aforementioned drug groups either 
as sole treatment or their use in combination with other 
drugs was also explored.
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INTRODUCTION
It is widely accepted that breastfeeding is the best way of  
ensuring a good start in an infant’s life as it not only has a 
favourable nutrient content but also provides passive im-
munity and various growth hormones to the breastfed 
infant[1-4]. However, there is always concern regarding the 
transfer of  medications taken by the mother to the infant 
via breast milk. To understand the safety of  medicines in a 
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nursing mother, it is important to elucidate the mechanism 
of  such drug transfer. 
The major determinant of  the transferability of  drugs 
from mother to baby via breast milk is usually calculated using 
parameters such as the physicochemical properties of  the 
drug and the composition of  the milk[4]. However, research 
has shown that active transport via efflux transporters may 
have a significant role in the transfer of  drugs from the 
maternal plasma to breast fed infant. It has been shown 
that breast cancer resistance protein (BCRP) (also known 
as ABCG2), belonging to the ATP-binding cassette (ABC) 
superfamily of  transporters is strongly induced during 
lactation[5]. There are also many other transporters belonging 
to the ABC family such as P-glycoprotein (P-gp) (also 
known as ABCB1 or MDR1) which like BCRP have some 
toxicological significance in lactation. Other transporters 
belonging to the solute carrier family such as the organic 
cation and anion transporters, peptide and nucleoside 
transporters also found in the mammary gland play an 
important role in the active transport of  many nutrients, 
endogenous substances and xenobiotics[6]. 
The protective role of  P-gp in the blood brain barrier 
is well established. It inhibits a wide variety of  substrates 
from entering the central nervous system[7]. The main fo-
cus of  research has so far been on the role of  these trans-
porters in the gastrointestinal tract and the blood brain 
barrier (BBB) affecting bioavailability of  drugs, pharma-
coresistance leading to ineffective drug treatment. Modu-
lation of  these efflux transporters can have an impact on 
drug absorption, disposition and consequently therapeutic 
outcome. However, we know that P-gp is also widely 
expressed in many other human tissues including the 
liver, kidneys, testes, placenta and the mammary epithelial 
cells[8]. It is also well known that these ABC transport-
ers play a crucial role in the protective mechanism during 
embryogenesis in the placenta which is continued during 
lactation providing foetal protection against naturally oc-
curring toxins[9]. Our area of  interest is the role of  these 
transporters in the lactating human mammary epithelial 
cells (HMEC) where they could potentially influence 
transfer of  drugs from mother to their breastfed baby via 
breast milk. However, this area remains poorly researched 
and there is lack of  controlled studies that can provide 
conclusive evidence. On the basis of  other organ systems, 
co-administration of  medications that are substrates or 
inhibitors of  these transporters in a nursing mother could 
have significant drug-drug interactions which may lead to 
adverse effects in their breastfed infant. Several in vitro and 
animal studies have been conducted which address this 
area of  concern. However, the applicability of  these in 
vitro findings may not always be conclusive and are often 
contradictory due to differences in experimental design 
and use of  species other than humans[10-12]. Most animal 
species such as rats and mice used in the laboratory have 
two genes (Mdr1a and Mdr1b) that code for P-gp, which 
further complicates issues regarding induction, expression 
and drug-drug interactions[11]. 
TRANSFER OF DRUGS FROM MATERNAL 
PLASMA TO THE BREASTFED INFANT
The transfer of  drugs from maternal plasma to breast 
milk occurs via passive and active mechanisms[9,13]. The 
critical determinants of  passive transfer include drug 
protein binding, drug ionisation and fat partitioning[4,13]. 
These factors can be used to predict milk to plasma (M:
P) ratio where passive diffusion is thought to predomi-
nate. Other pharmacokinetic parameters such as half-life 
of  the drug, protein binding, water and lipid solubility, 
route of  drug administration, bioavailability, dissocia-
tion constant, volume of  distribution, molecular size and 
ionisation potential can further help to determine the 
transfer of  drugs from mother’s plasma into the breast 
milk[14]. Drugs with the shortest plasma half-life, highest 
protein binding and lowest lipid solubility usually have 
the lowest ductal milk transport. The dose of  a drug that 
an infant receives during breastfeeding depends on the 
amount excreted into the breast milk, the daily volume of  
the milk ingested and the average plasma concentration 
of  the mother. Thus, M:P ratio has large inter-subject 
variability[15]. Although the transfer of  most drugs into 
breast milk can be explained by passive diffusion theo-
ries, a review of  the literature shows that there are several 
drugs where the actual measured M:P ratio is significantly 
greater than predicted[16-19]. Nitrofurantoin, acyclovir and 
cimetidine are some drugs which exhibited a significantly 
higher observed M:P ratio than predicted[5,7,16,18,20]. In one 
study nitrofurantoin had an observed M:P ratio of  6 as 
opposed to the predicted 0.28[17]. It has also been shown 
that several members of  the ABC drug efflux transport-
ers significantly affect the pharmacokinetic disposition 
of  drugs such as the quinolones, thereby increasing their 
secretion into breast milk[17,19]. 
ROLE OF EFFLUX TRANSPORTERS 
IN THE TRANSFER OF DRUGS FROM 
MATERNAL PLASMA TO THE BREAST 
FED INFANT
The extent of  the involvement of  these ABC transporters 
in the transfer of  many nutrients including essential 
vitamins and drugs into the breast milk has been recently 
considered[21]. There are several efflux transporters in 
human mammary epithelial cells that line the alveoli 
within the mammary gland[8,22,23]. This leads us to believe 
that there may be a more substantial role of  these 
transporter proteins in the transfer of  many compounds 
from maternal plasma to the breast milk than currently 
perceived. Alcorn et al[8] have shown that there is some 
of  variability between the level of  RNA expression of  
various transporters in the HMEC from lactating vs non 
lactating breast tissue, indicating a graded expression 
change during induction of  the lactation process that 
could lead to significant changes in substrate transport 
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during lactation. Using immunocytochemical analysis and 
functional studies in primary human mammary epithelial 
cells culture, our group have demonstrated the presence 
of  MDR1 (ABCB1), MDR3 (ABCB4) and MRP1 
(ABCC1) in these cells[21]. 
Gilchrist and colleagues showed that there is a stage 
dependent change in the expression of  transporters in 
rat mammary gland and isolated mammary epithelial or-
ganoids[24]. Using quantitative reverse transcription poly-
merase chain reaction, they demonstrated that the various 
solute carrier and ABC transporters showed a changing 
pattern in the different stages of  lactation. Ling et al[25] 
studied the M:P ratio of  cefepime, an actively transported 
drug at four and ten days post-partum in rats and found a 
significant reduction in the amount of  cefepime excreted 
at these two time points. This leads us to believe that as 
lactation progresses from stages of  mammogenesis to 
lactogenesis to galactopoiesis, changes in the expression 
of  efflux transporters along with changing hormones 
may influence the transfer of  endogenous and exogenous 
substances from mother to baby via breast milk. How-
ever, currently there are no studies in humans to confirm 
this. Our laboratory is presently investigating whether 
the expression of  efflux transporters in humans follow a 
stage dependent pattern as seen in animal studies. 
The expression of  MRP1 (ABCC1) and MDR1 (ABCB1) 
are significantly lower in the lactating HMEC as compared to 
non-lactating HMEC[8] whereas that of  BCRP is significantly 
higher[5]. It is important to note that there is a substantial 
overlap in the substrate specificities of  these transporters[6]. 
These findings highlight the importance of  possible drug-
drug interactions between various transporter substrates 
and/or inhibitors when co-administered at different stages 
of  lactation. In addition, it is important to take into account 
the localization of  these transporters, such that their presence 
in the apical surface (MDR1 and BCRP) may pump drugs 
into milk and further place the suckling infant at risk of  
xenobiotic exposure[20]. Alternatively, if  these transporters are 
located in the basolateral membrane of  the cell (MRP1), then 
the substrate will be pumped out of  the milk and into the 
mother’s blood, thereby reducing infant exposure. 
The active efflux transporters usually help in preventing 
accumulation of  drugs into the tissues as they work against 
a concentration gradient and push drugs from the tissues 
back into the blood[7,8,24]. There have also been reports 
of  transporter proteins being involved in the transfer of  
essential nutrients and vitamins to the breast fed infant 
which are mostly located in the basolateral side[7,22,26]. 
However, the extent to which they affect drug transfer 
in the mammary gland is not fully known[6]. Similar to 
P-gp, BCRP has a protective role at the blood side of  
many organ systems by facilitating the extrusion of  toxins, 
xenobiotics and drugs out of  the capillaries prior to 
interstitial accumulation with an important role being in the 
blood-placental barrier, where they protect the foetus from 
endogenous and exogenous toxins[27]. A current vexing 
question is how relevant is the role of  efflux transporters 
at other blood-tissue barriers such as in HMECs of  a 
lactating female who is breastfeeding her infant compared 
to the plethora of  studies examining gastrointestinal or 
BBB transport. Can P-gp or BCRP modulation by an 
inhibitor drug that the mother consumes cause less drug 
to be transferred to the breastfed infant via milk? Also if  
P-gp is located on the apical membrane of  the HMEC, 
the evidence that RNA expression of  P-gp is lower in the 
lactating HMEC[8] could have a relatively protective effect 
on the breastfed infant, by virtue of  less P-gp to excrete 
drug into the milk (Figure 1).
The expression of  BCRP in pregnant mice was found 
to be strongly induced during late pregnancy and lacta-
tion, which is the opposite to that of  P-gp[5]. Lindner and 
colleagues reported that the expression of  BCRP in the 
mammary glands of  several species of  animals including 
sheep, goats and cows were significantly increased (up to 
10 fold) during pregnancy and lactation[28]. Both P-gp and 
BCRP are located in the apical membrane of  alveolar epi-
thelial cells of  the mammary gland and actively transport 
their substrates into breast milk as confirmed by animal 
studies[5,20]. BCRP has a significant role in accumulation 
of  drugs and xenotoxins in breast milk which could be 
either beneficial or detrimental to the breastfed infant’s 
health depending on the drug administered[29]. A BCRP 
substrate that is toxic can accumulate in milk and result 
in adverse effects in the infant whereas the accumulation 
of  a drug such as aciclovir could be beneficial in reduc-
ing transmission of  milk borne viruses from mother to 
baby. There is some evidence that the role of  P-gp in the 
lactating HMEC is relatively insignificant in the transfer 
of  medications which could possibly be due to its down 
regulation in lactation. Animal studies have shown that 
the transfer of  nelfinavir, a known P-gp substrate is not 
affected by P-gp in the mammary gland[28]. However, 
many other studies have shown that the role of  BCRP is 
much more significant, given that BCRP is strongly in-
duced during pregnancy and lactation[5,16,18,30]. 
As there is a significant overlap between P-gp, BCRP, 
other efflux transporters and CYP3A4 substrates[6], it 
is crucial that each drug or the combination of  drugs is 
considered with respect to these transporters and metab-
olism pathways in addition to the usual pharmacokinetic 
parameters to ensure minimum inadvertent exposure to a 
breastfed infant.
SPECIFIC DRUGS
Antidepressants - selective serotonin reuptake 
inhibitors
Post-natal depression is considered to be a significant prob-
lem in women of  child bearing age with approximately 14% 
of  all women affected by this condition at some stage[31]. 
Psychotherapy is considered quite useful in the manage-
ment of  post natal depression but due to a lack of  adequate 
service provision in the community, it is often necessary to 
treat women with pharmacotherapeutic agents[31]. Selective 
serotonin reuptake inhibitors (SSRI) are considered the 
mainstay of  postnatal depression due to their perceived low 
transferability into breast milk and safety profile unlike tri-
cyclic antidepressants that may have a higher breast milk ex-
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safety data in this population, was found to cause no im-
mediate adverse effects in an exclusively breastfed 32 d 
old infant[42]. The measured M:P ratio and the relative in-
fant dose for this drug were also found to be very low[43]. 
Venlafaxine, another SNRI was found to induce BCRP in 
brain tissue and is thought to be a P-gp substrate whereas 
desvenlafaxine, the active metabolite of  venlafaxine was 
found to have no effect on BCRP induction or P-gp 
modulation[44,45]. 
Another case study on sertraline reported signs of  
serotonergic overstimulation in a preterm baby whose 
mother had therapeutic levels of  both the drug and its 
metabolite, desmethylsertraline. The symptoms disap-
peared on discontinuation of  breastfeeding[46]. This ad-
verse reaction was attributed to immaturity in the devel-
opment of  the infant’s clearance mechanisms and lack of  
development of  the BBB. Interestingly, the plasma sertra-
line and desmethylsertraline levels of  the infant were sig-
nificantly below the threshold levels considered to cause 
symptoms. There was no record of  other medications 
that may have been used by the mother acutely or long 
term during the postpartum period. Hence, it raises the 
question of  whether another drug(s) administered acute-
ly, able to modulate P-gp activity, could have resulted in 
the adverse effects experienced by the breastfed baby. 
The lack of  a full medication record makes it difficult to 
draw conclusions regarding the drug-drug interactions. 
Current guidelines place paroxetine and sertraline 
amongst the recommended antidepressant drugs for use 
in lactation. It is imperative that infants of  mothers tak-
ing these drugs are regularly monitored for adverse ef-
fects especially when the mothers are also treated acutely 
or chronically with another pharmacologic agent that 
could modulate active transporters as these drugs have 
the potential to do[35,47]. 
Antipsychotics
About one third of  pregnant women with psychotic ill-
ness use antipsychotics at least once during pregnancy or 
whilst breastfeeding[48]. About 10% of  women of  child 
bearing age have a postpartum psychiatric disorder, with a 
significant number warranting the use of  an antipsychotic 
medication[49]. Although the second generation (atypical) 
posure leading to reduced usage[31]. The recommended SS-
RIs for post-natal depression are sertraline and paroxetine 
as they have been widely studied and are not associated with 
many adverse effects[32]. Fluoxetine and citalopram have 
measurable plasma levels in some infants[33,34]. However, 
these levels were usually low. Some women may choose to 
continue using one of  the other SSRIs that they have been 
stabilised on before and during pregnancy. Nonetheless, 
most SSRIs are considered to be fairly safe in breastfeeding. 
Paroxetine and fluoxetine are thought to be P-gp sub-
strates[35]. Citalopram and its enantiomer, escitalopram 
have also been found to be substrates of  P-gp in animal 
studies as demonstrated by Weiss et al[36]. The implica-
tions and relevance for this evidence in lactation remains 
elusive. However, in vivo it has been shown that the peak 
plasma concentration and area under the curve of  par-
oxetine, is significantly increased by itraconazole (a P-gp 
and CYP3A4 inhibitor)[37]. Again, this could mean that a 
P-gp substrate which normally has low transferability into 
breast milk may potentially transfer in significantly higher 
amounts if  given with a P-gp inhibitor.
Furthermore, it has been found that sertraline, a P-gp 
substrate and inhibitor, can modulate P-gp both in vivo 
and in vitro at the BBB and blood testes barrier sites[38]. 
This finding suggests that concurrent administration 
of  other P-gp substrates with sertraline potentially in-
crease CNS penetration of  that substrate[39]. Again, the 
significance and implication of  this finding in lactation 
needs to be investigated further as another study found 
modulation of  P-gp by sertraline was site specific with 
different tissues reacting to sertraline in different ways[40]. 
It is important to investigate whether this finding has any 
potential for causing interactions in the lactating HMEC 
leading to adverse effects in the breastfed infant as this 
tissue was not directly investigated. A different study by 
Bhuiyan et al[41] found that a single dose of  sertraline does 
not affect the pharmacokinetic profile of  fexofenadine, 
another P-gp substrate but paroxetine and fluvoxamine 
do. There was no data with regards to BCRP substrate 
specificity in the selective serotonin reuptake inhibitors. 
Of  other new antidepressants, duloxetine, which is a 
serotonin noradrenaline reuptake inhibitor (SNRI), not 
used often in pregnancy and breastfeeding due to lack of  
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Figure 1  Schematic representation of expected localisation of drug efflux transporters in the human mammary epithelial cells. P-gp: P-glycoprotein; BCRP: 
Breast cancer resistance protein; MRP: Multidrug resistance protein.
antipsychotics are considered the best treatment option 
for schizophrenia, female patients who are pregnant or 
breastfeeding are often excluded from this treatment op-
tion due to safety concerns.
Several atypical antipsychotics are substrates for P-gp 
in therapeutic concentrations. These include amisulpride, 
aripiprazole, olanzapine, risperidone, quetiapine and pali-
peridone, with quetiapine and risperidone having high 
affinity for P-gp[50]. Friedman et al[50] found olanzapine 
and quetiapine to be P-gp substrates whereas another 
in vitro study by Müller et al[47] contradicted this finding 
and identified that quetiapine, haloperidol, olanzapine 
and clozapine are not P-gp substrates. As the first study 
assessed P-gp activity by measuring ATPase activity 
whereas the second study was an inhibition study carried 
out using Caco-2 cell monolayers, these different meth-
ods of  P-gp substrate identification may be responsible 
for their different conclusions. Our studies using Caco-2 
monolayers support the latter work, demonstrating the 
lack of  P-gp mediated efflux associated with quetiapine 
and olanzapine. Hence, it is important to exercise caution 
when interpreting results from different cell lines and 
membrane systems[35]. In vivo studies using knockout and 
wild type mice may be more reliable and may provide a 
clearer picture of  functional consequence[51]. However, it 
is worth noting that these rodents may have more than 
one gene coding for P-gp, hence may differ from human 
P-gp structurally.
Several antipsychotics including clozapine, quetiapine, 
paliperidone and chlorpromazine also exert some inhibi-
tory effects on BCRP[52]. Risperidone has major inhibi-
tory effects on BCRP, making it a potential contributor 
of  adverse effects with co-administered with BCRP mod-
ulators such as commonly prescribed pantoprazole and 
omeprazole[52,53]. Aripiprazole, an atypical antipsychotic 
was found to have an inhibitory effect on BCRP[54]. Most 
antipsychotics are thought to act as inhibitors of  P-gp/
BCRP and therefore can influence plasma and brain con-
centrations of  other substrates[55]. 
A prospective controlled observational study of  olan-
zapine use in 30 pregnant women who were taking olan-
zapine during pregnancy and whilst breastfeeding found 
that no adverse effects were imputable to the use of  
olanzapine by the mother. However, the rate of  breast-
feeding was significantly lower in the treated group. Also 
three out of  thirty babies (10%) experienced withdrawal 
symptoms after birth and interestingly all three mums 
were on multiple medications including zuclopenthixol, 
lithium and paroxetine[56]. A case report of  a lactating 
patient who was taking olanzapine after a psychotic epi-
sode reported low infant plasma levels of  olanzapine 
and no adverse effects in the breastfed baby[57]. Another 
case study reported no adverse effects in the infant of  a 
woman who was initiated on olanzapine during her third 
trimester and continued breastfeeding six months post-
partum[49]. There is no mention of  concurrent therapy if  
any. A case report of  risperidone by Lutz et al[58] showed 
that risperidone, a P-gp substrate, and its metabolite 
9-hydroxyrisperidone were moderately transferred into 
breast milk. A dose (concentration) of  less than 10% 
of  that received by the mother (on a mg/kg basis) has 
been suggested and is widely accepted as a “safe” dose 
(or concentration) in the infant[45]. Although, the amount 
transferred (4.3% of  maternal dose) was below the no-
tional 10% threshold, the mother was encouraged not to 
breastfeed due to concerns for the safety of  her infant. 
Again, no information was provided on whether the 
mother was on any other concurrent medications. Cer-
tainly, we would prefer clinical studies to state that there 
were no other medications in the study rather than just 
omitting this crucial information. Often when the focus 
is on one particular drug and snapshot studies such as M:
P ratio are being investigated, other medications do not 
make it into the clinical notes. Given our presumption 
that in psychiatry multiple medications are often used 
concurrently, this makes subsequent contextual analysis 
very difficult. Furthermore, a series of  case reports by Il-
let’s group[59] confirmed the findings from the first report 
that risperidone on its own is not transferred into breast 
milk in levels high enough to be considered a clinical is-
sue for the safety of  the breastfed infant. 
Ziprasidone, an atypical antipsychotic was found to be 
excreted in very low concentrations in breast milk from 
a treated patient while no adverse effects were observed 
in the infant of  a different patient with psychotic depres-
sion treated with citalopram and ziprasidone[60,61]. It is not 
known whether ziprasidone is a P-gp substrate or BCRP 
modulator at this time[55]. Further research and more long 
term studies are warranted to ensure the safety of  the 
newer antipsychotics on infant growth and development.
Amisulpride, another atypical antipsychotic has been 
used in one woman who was breastfeeding her 13 mo 
old infant. An unusually high M:P ratio for this drug 
compared to predicted values based on pharmacoki-
netic parameters was found[62]. This high M:P ratio was 
attributed to amisulpride being a P-gp substrate[47,63]. 
Amisulpride used in conjunction with desvenlafaxine in a 
partially breastfed infant yielded no higher than expected 
relative infant dose. Given that Amisulpride is a P-gp 
substrate, the combination with desvenlafaxine did not 
appear to alter its pharmacokinetics reaffirming the in vi-
tro evidence that desvenlafaxine does not modulate efflux 
transporters[44,45]. Olanzapine is considered a weak sub-
strate whereas data for quetiapine are contradictory with 
one study identifying it as a substrate and the other not 
a substrate[47,63]. Another in vitro study found that olan-
zapine and risperidone may inhibit P-gp activity. Most 
other drugs in this therapeutic group though, such as 
clozapine, haloperidol chlorpromazine and quetiapine did 
not inhibit P-gp[64]. Much of  the studies discussed above 
were cell based, and projecting this data into clinical stud-
ies has been sorely lacking. Nonetheless, it is appropriate 
to exercise caution when using these agents especially in 
combination with another agent which may modulate 
P-gp especially in a lactating mother who is breastfeeding 
or exclusively breastfeeding, given that some studies sup-
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port the notion that blocking P-gp (or other efflux trans-
porters) can elevate milk concentration of  these drugs.
Antiepileptic drugs 
Many women with epilepsy require treatment with anti-
epileptic drugs (AED) during pregnancy and post-partum 
when they may be breastfeeding their baby. Usually 
women with epilepsy do not have a choice to discontinue 
treatment while pregnant or breastfeeding. All antiepilep-
tic drugs are transferred across the placenta and to a lesser 
extent into breast milk in varying amounts. The implica-
tions of  AED exposure via breast milk is still not fully 
understood. A large prospective study of  epileptic moth-
ers on AED prenatally showed adverse development in 
their children regardless of  breastfeeding status[65,66]. Some 
other large studies also showed no damaging effects on 
neurodevelopment of  breastfed children of  women who 
were prescribed AED during breastfeeding[67]. Neverthe-
less, most antiepileptic drugs are known to be teratogenic 
and increase the risk of  foetal malformations[68]. 
The role of  efflux transporters such as the MRP 
group and P-gp in the transport of  AED showed variable 
results[69]. Luna-Tortós et al[10] initially found that several 
AED were substrates of  the human P-gp. Lamotrigine 
and phenobarbital were also found to be MRP substrates. 
However, in a subsequent study they indicated that 
AED were not substrates of  the human P-gp and that 
the different interpretations from the two studies were 
attributed to the different experimental designs used[11]. 
Several other studies also suggested that AED were not 
human P-glycoprotein substrates[12,68-70]. Studies performed 
in animals yielded conflicting results showing that AED 
were indeed substrates of  P-gp[71-74]. The variability in 
these results may be attributed to the differences between 
human and rat P-gp. The cell lines and experimental 
designs used for conducting these studies can also have 
a significant impact on the results[71]. Another study in 
mice found that levetiracetam, topiramate and phenytoin 
demonstrate biphasic modulation of  P-gp in BBB 
whereby at therapeutic doses they act as inducers of  
efflux. Sodium valproate and lamotrigine were found 
not to interact with P-gp[11,73,75]. Carbamazepine, itself  
was not a P-gp substrate but its metabolites were[76,77]. 
Dickens and co-workers also identified that lamotrigine 
and carbamazepine were not affected by P-gp[78,79]. 
Several case reports show that lamotrigine was transferred 
into breast milk in moderate amounts and in one case, 
where the mother was on 850 mg/d, it led to a severe 
apnoeic reaction in the exclusively breast fed infant[80]. 
It is not specified whether the mother was on any other 
medications at the time that could have contributed to this 
adverse reaction. Another study has shown that although 
lamotrigine’s M:P ratio is highly variable, it is transferred 
into breast milk in moderate amounts[67]. 
In vitro studies carried out on MDCKII cells by 
Nakanishi et al[75] found that phenobarbital, clobazam, 
zonisamide, gabapentin and levetiracetam were BCRP 
substrates. Contrary to their findings, another group 
found that phenobarbital as well as other AED including 
phenytoin, ethosuximide, primidone, sodium valproate, 
carbamazepine, clonazepam, and lamotrigine did not in-
teract with BCRP[79]. The differences in the experimental 
design and human and animal transporters may partly ex-
plain the variations in these results, with the animal stud-
ies appearing to favour anti-epileptic P-gp affinity while 
the human P-gp studies do not support this[68,77,79]. 
It is interesting that genetic polymorphism of  P-gp 
is not associated with drug response in epileptic pa-
tients[80,81]. Again this concurs with the evidence that 
AED may not be transported by efflux transporters such 
as P-gp and BCRP[81]. Weiss et al[36] indicate that P-gp may 
not be of  great significance in the transport of  AED. 
Further studies are required to elucidate if  there are any 
other active transport mechanisms which may have sig-
nificant clinical implications in breastfeeding mothers. 
DISCUSSION
It is well known that exposure to medications in utero is 
significantly higher than exposure via breast milk. How-
ever, exposure via breast milk is voluntary as opposed to 
in utero where they are inadvertently exposed to medica-
tions through placental transfer. Infant exposure to medi-
cations via breast milk, especially in the first six months 
when the infant is likely to be exclusively breastfed can 
have severe adverse effects possibly due to the underde-
veloped metabolic and excretory mechanisms in the infant 
during this time. Hence, even small exposure to medica-
tion via breast milk may result in accumulation of  drug 
at a level that may cause side effects in the infant, which 
calls into question the notional 10% of  mother’s plasma 
concentration in the milk as the threshold for concern. 
It is also important not to discontinue breastfeeding un-
necessarily as there are many benefits associated with 
breastfeeding. Drug pharmacokinetic parameters usually 
give a good indication of  the transferability of  the drug 
from mother to baby via breast milk. However, there 
have been incidents when the actual M:P ratio of  certain 
drugs have been much higher than predicted which is 
thought to be due to the involvement of  active transport 
mechanisms. Yet, the significance of  such active trans-
port mechanisms and efflux transporters in the human 
mammary epithelial cells is still not fully understood. In 
vivo and in vitro studies have confirmed their presence but 
the clinical relevance of  their role remains elusive. There 
is also contradiction and conflict with regards to the cur-
rent findings as to whether particular drugs are substrates 
of  these transporters and the degree of  commonality 
between transporter substrates. Data can vary depending 
on the experimental design and the cell lines used. There 
is also significant inter species variability which can affect 
interpretation of  results. Nonetheless, it is important to 
exercise caution when prescribing CNS acting drugs, such 
as psychotropics to breastfeeding mothers as even small 
unnecessary drug exposure may have disturbing side ef-
fects in the very young.
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